Search results for
5187 items
Equality and Human Rights Consultation - NICE TA - Tocilizumab for Treating Giant Cell Arteritis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Avelumab for Merkel Cell Carcinoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Prior Chemotherapy Regimen
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer after Radioactive Iodine [ID1059]
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Cabozantinib Treating Medullary Thyroid Cancer
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Tivozanib for Treating Renal Cell Carcinoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Brodalumab for Treating Moderate to Severe Plaque Psoriasis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Obinutuzumab for Untreated Advanced Follicular Lymphoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Regorafenib for Previously Treated Unresectable Hepatocellular Carcinoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pertuzumab with Trastuzumab and Docetaxel for Treating HER2-Positive Breast Cancer
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Sofosbuvir-Velpatasvir-Voxilaprevir for Treating Chronic Hepatitis C
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer after Platinum-Based Chemotherapy
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Lesinurad for Treating Chronic Hyperuricaemia in People with Gout
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Apremilast for Treating Moderate to Severe Plaque Psoriasis [ID987] (Rapid Review of TA368)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Dapagliflozin in Triple Therapy for Treating Type 2 Diabetes
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Azacitidine for Treating Acute Myeloid Leukaemia with More than 30% Bone Marrow Blasts
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Canagliflozin, Dapagliflozin and Empagliflozin as Monotherapies for Treating Type 2 Diabetes
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the